Suppr超能文献

丙型肝炎患者中,谷草转氨酶/谷丙转氨酶比值≥1并不能诊断为肝硬化。

AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C.

作者信息

Reedy D W, Loo A T, Levine R A

机构信息

Department of Medicine, State University of New York Health Science Center at Syracuse, USA.

出版信息

Dig Dis Sci. 1998 Sep;43(9):2156-9. doi: 10.1023/a:1018888021118.

Abstract

Medical guidelines for interferon-alpha2a or -alpha2b (IFN-alpha) treatment of chronic hepatitis C virus (HCV) infection depend upon baseline liver histology. A better long-term response to IFN-alpha therapy correlates with less inflammation and absence of cirrhosis. It has been suggested that the presence of cirrhosis in patients with chronic hepatitis C virus infection may be predicted based on an AST/ALT ratio > or = 1. This study was designed to determine if the presence of cirrhosis can be predicted in patients with chronic HCV infection by such a ratio. Seventy-seven patients, including 23 cirrhotics, with chronic HCV infection were studied. Serum ALT, AST, and HCV-RNA levels and hepatic activity index (HAI), reflecting histologic inflammation in all liver biopsies, were assessed. AST/ALT ratios and mean ALT, AST, and HCV-RNA were determined for both cirrhotic and noncirrhotic patients. HAI was correlated with ALT, AST, and HCV-RNA levels, the latter determined by quantitative RT-PCR. The likelihood ratio (LR) and positive predictive value of an AST/ALT ratio > or = 1 for cirrhosis was 7.3 and only 77%, respectively. In cirrhotics vs noncirrhotics, there were no significant differences between mean serum ALT (149 +/- 28 vs 176 +/- 17 units/liter), AST (139 +/- 28 vs 102 +/- 8 units/liter), or HCV-RNA levels (589,160 +/- 147,053 vs 543,915 +/- 75,497 copies/ml), respectively. There was a significant, but clinically weak, correlation between serum ALT and HAI (r = 0.234), and none between HAI and either serum AST or HCV-RNA levels. Our results support the need for a liver biopsy prior to treatment of chronic HCV infection, since the AST/ALT ratio fails to predict accurately the presence of cirrhosis.

摘要

α-干扰素2a或α-干扰素2b(IFN-α)治疗慢性丙型肝炎病毒(HCV)感染的医学指南取决于基线肝脏组织学情况。对IFN-α治疗的长期反应更好与炎症较轻及无肝硬化相关。有人提出,慢性丙型肝炎病毒感染患者中肝硬化的存在可根据AST/ALT比值≥1来预测。本研究旨在确定通过这样的比值能否预测慢性HCV感染患者中肝硬化的存在。对77例慢性HCV感染患者进行了研究,其中包括23例肝硬化患者。评估了血清ALT、AST和HCV-RNA水平以及反映所有肝活检组织学炎症的肝脏活动指数(HAI)。测定了肝硬化患者和非肝硬化患者的AST/ALT比值以及平均ALT、AST和HCV-RNA水平。HAI与ALT、AST和HCV-RNA水平相关,后者通过定量逆转录聚合酶链反应测定。AST/ALT比值≥1对肝硬化的似然比(LR)和阳性预测值分别为7.3和仅77%。在肝硬化患者与非肝硬化患者中,平均血清ALT(149±28对176±17单位/升)、AST(139±28对102±8单位/升)或HCV-RNA水平(589,160±147,053对543,915±75,497拷贝/毫升)之间分别无显著差异。血清ALT与HAI之间存在显著但临床意义较弱的相关性(r = 0.234),而HAI与血清AST或HCV-RNA水平之间均无相关性。我们的结果支持在治疗慢性HCV感染之前进行肝活检的必要性,因为AST/ALT比值无法准确预测肝硬化的存在。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验